VISTA (PD-1H)和PVR (CD155)在非小细胞肺癌中的表达作用与临床意义：一项系统综述
Role and clinical significance of VISTA (PD-1H) and PVR (CD155) expression in non-small cell lung carcinoma: a systematic review.
作者
作者单位
- Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland.
- Department of Histology and Cell Pathology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
- IIIrd Department of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
摘要
中文
免疫检查点阻断已改善了非小细胞肺癌（NSCLC）的预后，但原发性和获得性耐药仍然常见。VISTA（PD-1H）和CD155（脊髓灰质炎病毒受体，PVR）是新兴的免疫调节通路，可能有助于免疫逃逸并代表潜在的治疗靶点。因此，本系统综述旨在评估CD155（PVR）和VISTA（PD-1H）在NSCLC中的表达模式、分子功能和临床意义。我们对评估VISTA和/或CD155在NSCLC中表达、功能和临床相关性的研究进行了系统综述。检索了PubMed、Scopus、Embase和Web of Science，截止至2025年9月。符合条件的研究包括原始人类、体内和体外研究。使用纽卡斯尔-渥太华量表（NOS；人类研究）和SYRCLE工具（动物研究）评估偏倚风险。该方案已在PROSPERO注册。51项研究符合纳入标准（22项VISTA；29项CD155）。VISTA主要在基质细胞和免疫细胞区室中报道，并与免疫调节功能相关，但现有证据不支持其与生存期的一致性关联。CD155主要在肿瘤细胞上表达，与免疫抑制微环境相关，并在选定的队列中更一致地与不良预后相关，特别是当与程序性死亡配体1（PD-L1）共表达时。这两条通路似乎都参与了NSCLC的免疫调节。VISTA作为预后生物标志物的证据仍不确定，而CD155显示出与不良结局更可重复的关联，支持其作为预后标志物和治疗靶点的进一步评估。
English
Immune checkpoint blockade has improved outcomes in non-small cell lung carcinoma (NSCLC), yet primary and acquired resistance remain common. VISTA (PD-1H) and CD155 (poliovirus receptor, PVR) are emerging immune-regulatory pathways that may contribute to immune escape and represent potential therapeutic targets. Thus, this systematic review aimed to evaluate the expression patterns, molecular functions, and clinical significance of CD155 (PVR) and VISTA (PD-1H) in NSCLC. We performed a systematic review of studies assessing the expression, function, and clinical relevance of VISTA and/or CD155 in NSCLC. PubMed, Scopus, Embase, and Web of Science were searched through September 2025. Original human, in vivo, and in vitro studies were eligible. Risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS; human studies) and SYRCLE's tool (animal studies). The protocol was registered in PROSPERO. Fifty-one studies met the inclusion criteria (22 VISTA; 29 CD155). VISTA was predominantly reported in stromal and immune-cell compartments and linked to immune-regulatory functions, but available evidence did not support a consistent association with survival. CD155 was mainly expressed on tumour cells, associated with an immunosuppressive microenvironment, and more consistently related to adverse prognosis in selected cohorts, particularly when co-expressed with programmed death-ligand 1 (PD-L1). Both pathways appear involved in immune modulation in NSCLC. Evidence for VISTA as a prognostic biomarker remains inconclusive, whereas CD155 shows a more reproducible association with unfavourable outcomes, supporting its further evaluation as a prognostic marker and therapeutic target.
分类与指标
- 研究类型
- 综述Meta
- 病种
- 肺癌
- JCR 分区
- Q2
- 影响因子
- 3.4
- 新锐分区
- 3区